The randomised controlled RECOVERY trial1 has met its primary endpoint of reduced 28-
day mortality. We congratulate the RECOVERY Collaborative Group for this excellent study …

We previously reported a weak immune response after two doses of the vaccine against
SARS-CoV-2 in 36 (41%) of 88 recipients of allogeneic hematopoietic stem-cell …

Three reports address the protection of the vulnerable population of patients with
hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest …

Letermovir potently inhibits the cytomegalovirus (CMV)-terminase complex. Letermovir
primary prophylaxis given for the first 3 months after allogeneic hematopoietic cell …

Background Cytomegalovirus (CMV) infection and disease (CMV episodes) are global
concerns after allogeneic hematopoietic stem cell transplantation (HSCT). They affect …

Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19
and have altered immune responses to vaccination. We sought to evaluate the dynamics of …

Neutrophilic dermatoses (NDs) are characterized by dense infiltrates of mature neutrophils
typically located in the upper dermis. Despite having dissimilar clinical presentations …

We report the results of the French Temporary Authorization of Use (ATU) compassionate
program of letermovir for primary prophylaxis conducted in 21 transplant centers. Patients …

Abstract T‐prolymphocytic leukemia (T‐PLL), a rare aggressive mature T‐cell disorder,
remains frequently resistant to conventional chemotherapy. Studies have suggested that …

Background Targeting immune checkpoints that inhibit antitumor immune responses has
emerged as a powerful new approach to treat cancer. We recently showed that blocking the …